Topline results from the Phase 3 REVEAL-1 trial demonstrate that subcutaneous elegrobart achieved rapid, clinically meaningful reductions in proptosis and diplopia in active Thyroid Eye Disease patients with convenient Q4W or Q8W dosing.
OphthalmologyPHARMACOLOGYTRIALS < class="penci-entry-title entry-title grid-title penci_grid_title">Elegrobart reduces proptosis in active thyroid eye disease